Johnson & Johnson and a subsidiary's $33 million deal with state attorneys general Wednesday covers misrepresentations over manufacturing practices for drugs such as Tylenol, Benadryl and others. Under the settlement agreement, McNeil, a Johnson & Johnson company, will pay $33 million.
The lawsuit alleges McNeil-PPC Inc. illegally promoted their over-the-counter drugs as meeting federal standards for manufacturing, when there were significant issues with the drugs' quality and effectiveness.
McNeil operated a plant in Fort Washington, Montgomery County and recalled hundreds of millions of packages of drugs it manufactured between 2009 and 2011, including many for pediatric use. "It's essential that people who buy and consume these products be able to do so with confidence, and without fear that they may be tainted in some way, or manufactured in substandard facilities".
"We're proud Pennsylvania helped lead this national effort to ensure health care companies are held accountable when they mislead customers about the quality of the products they put into the marketplace", said Attorney General Josh Shapiro, who spearheaded the effort.
Snapdragon 835 Confirmed for OnePlus 5
We expected to see a black color variant of the OnePlus 5 thanks to the success of the midnight black edition of the OnePlus 3T . OnePlus announced the OnePlus 3 and OnePlus 3T past year , and with no doubt, both the devices gained wide popularity worldwide.
At the time McNeil-PPC paid a criminal fine of $20 million and forefeited another $5 million.
They claimed that McNeil misrepresented its compliance federal manufacturing rules and the quality of its over-the-counter drugs. The state's share of that settlement is $531,816 and will go into the general fund. Neighboring states joining in the settlement include Illinois, Indiana, Ohio, Tennessee, Virginia, and West Virginia. Class I recalls involve a reasonable probability that use or exposure to the drug may result in serious detrimental health consequences or death.
Fail to identify or provide information to participating Attorneys General within 60 days of a written request about vendors or warehouses in which recalled OTC drugs were distributed in their state.